Shares of Amgen rise after the company announces positive initial trial results from its experimental drug used to treat non-small-cell lung cancer patients.
In the short run the stock of this biotech giant could bounce as momentum has slowed, but the bigger picture is for further weakness.
Cara Therapeutics surges after announcing positive results for treatment of kidney disease-related itchiness.
Israeli drugmaker says its payment of $85 million to the state is not an admission of wrongdoing; Johnson & Johnson subsidiary Janssen Pharmaceuticals meanwhile also defends company and says its open to a resolution.
What are insiders buying as the market sells off in recent trading sessions?
The drugmaker files suit against the U.S. Department of Health and Human Services and Centers for Medicare and Medicaid Services in order to protect Medicaid patient access to its Acthar gel.
Merck agrees to buy privately held Peloton Therapeutics for $1 billion in cash, giving it access to Peloton's molecular therapy treatments for patients with cancer and other non-oncology diseases.
Merck says one of its key cancer-fighting drugs, Keytruda, failed to meet its stand-alone goal of treating an aggressive type of breast cancer.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.